These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28408837)

  • 1. Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population.
    Jia L; Wang Z; Men J; Cai H; Wei M
    Ther Clin Risk Manag; 2017; 13():421-425. PubMed ID: 28408837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.
    Zhang J; Chen Z; Chen C
    Meta Gene; 2016 Sep; 9():197-209. PubMed ID: 27617219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing.
    Ruaño G; Thompson PD; Villagra D; Bower B; Kocherla M; Yazdanpanah G; Seip RL; Windemuth A; White CM; Duconge J; Holford TR; Wu AH
    Per Med; 2008 May; 5(3):225-232. PubMed ID: 29783498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
    Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of
    Holail J; Mobarak R; Al-Ghamdi B; Aljada A; Fakhoury H
    Drug Metab Pers Ther; 2022 Apr; ():. PubMed ID: 35365981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
    Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
    J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.
    Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA
    Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts).
    Chertovskikh YV; Malova EU; Maksimova NR; Popova NV; Sychev DA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S17-8. PubMed ID: 26639691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.